A Phase II Randomized Study Comparing Low Dose Alemtuzumab and Cyclosporine With Standard of Care for the Prevention of Chronic Extensive GVHD for Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Hematological Malignancies.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2016
At a glance
- Drugs Alemtuzumab; Ciclosporin; Methotrexate; Mycophenolate mofetil
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 21 Jun 2016 Status changed from recruiting to completed.
- 08 Nov 2008 New trial record.